BioCentury
ARTICLE | Company News

Zai builds cancer combo strategy with rights to Incyte's PD-1 mAb

July 2, 2019 11:40 PM UTC

Having gained rights to Incyte’s PD-1 inhibitor, Zai rolled out an immuno-oncology combination strategy it thinks can carve out a space in the crowded Chinese checkpoint inhibitor field.

Zai Lab Ltd. (NASDAQ:ZLAB) licensed exclusive rights to anti-PD-1 mAb INCMGA0012 from Incyte Corp. (NASDAQ:INCY) in China, Hong Kong, Macao and Taiwan. Incyte will receive $17.5 million up front and up to $60 million in milestones, plus tiered low to mid-twenties royalties...